Skip to main content
Izotropic Corporation logo

Izotropic Corporation — Investor Relations & Filings

Ticker · IZO ISIN · CA46604F1099 LEI · 529900IZ5PIVM7X6S027 CSE Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2024-04-02 Regulatory Filings
Country CA Canada
Listing CSE IZO

About Izotropic Corporation

https://izocorp.com/

Izotropic Corporation develops and commercializes diagnostic medical devices, specializing in advanced breast cancer detection technology. Its flagship product is IzoView, a dedicated Breast CT imaging platform. IzoView utilizes high-resolution, true 3D imaging without requiring breast compression, offering superior spatial resolution compared to traditional modalities. The system is purpose-built to improve diagnostic accuracy and patient comfort, particularly targeting the 50% of women with dense breast tissue where conventional screening tools are often inadequate. Izotropic is currently advancing IzoView through pivotal clinical studies toward product launch and commercialization.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'Certification of Interim Filings Venture Issuer Basic Certificate' under Form 52-109FV2. It is signed by the CFO certifying the review and fair presentation of the Interim Financial Report and Interim MD&A for the period ended January 31, 2024. The document explicitly states it is a certification and does not contain the actual financial data or detailed interim report itself. It is a regulatory certification attesting to the accuracy of the interim filings rather than the filings themselves. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the Interim Report (IR). The document length is short (3040 characters), consistent with a certification letter rather than a full interim report.
2024-04-02 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the three and nine months ended January 31, 2024. It contains detailed management commentary on financial condition, operational performance, regulatory updates, business development, and outlook. It references interim financial statements prepared under IAS 34 and IFRS, indicating it is a quarterly or interim report. The document is substantive and lengthy (15,000 characters), containing forward-looking statements and detailed operational updates, which aligns with the characteristics of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2024
2024-04-02 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements (Unaudited)' for the three and nine months ended January 31, 2024 and 2023. It contains detailed financial statements including statements of financial position, comprehensive loss, changes in shareholders' equity, cash flows, and notes to the financial statements. The document explicitly states it is prepared in accordance with IAS 34 Interim Financial Reporting and IFRS, and it is unaudited. The presence of interim financial data for a period shorter than a full fiscal year, along with detailed financial statements and notes, clearly identifies this as an Interim / Quarterly Report. The document is not a full annual report, nor is it an announcement or certification. It contains substantive financial data and analysis for the interim period. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). 9M 2024
2024-04-02 English
News release - English.pdf
Regulatory Filings
2024-01-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release from Izotropic Corporation providing updates on regulatory status with the FDA and operational activities. It discusses recent meetings with the FDA, ongoing correspondence, and business development efforts including potential mergers and funding. There are no financial statements, earnings data, or detailed financial analysis present. The document is primarily an operational and regulatory update communicated via a news release format. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a formal regulatory filing or certification. The content aligns best with a Regulatory Filings (RNS) category, which covers general regulatory announcements and miscellaneous filings that do not fit other specific categories. The document length (9415 characters) and content confirm it is a substantive update rather than a brief announcement or report publication notice.
2024-01-09 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-01-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.